Abstract
Chromodomain helicase DNA Binding protein 7 (CHD7) modulates chromatin remodeling during genome maintenance; however, its role in pancreatic cancer (PAC) is not known. We recently identified CHD7 as a novel gemcitabine (GEM) sensitivity gene through a synthetic lethal siRNA screen in human PAC cells. The goal of this study was to determine if CHD7 can function as a prognostic biomarker in patients with early-stage PAC treated with resection followed by adjuvant GEM.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
